The Antibody Technology Group employs various methods of antibody generation including antibody phage display and conventional hybridoma technology. Phage display offers the flexibility of generating antibodies against difficult targets as well as fully human antibodies for therapeutic purposes.
Traditional hybridomas from mouse immunization are useful for generating high affinity monoclonal antibodies for diagnostic reagents. Both in vitro and in vivo approaches are used depending on the target antigen and eventual application of the antibody.
The Antibody Technology Group develops antibodies and immunoassays to support drug discovery projects within ETC. Immunoassays commonly employed include western blotting, ELISA, flow cytometry, and immunohistochemistry. In addition, we collaborate with external partners to generate antibodies for therapeutic and diagnostic purposes. We aim to work on projects that would have a positive clinical impact or a commercializable outcome.